Early research (Phase 1)Active Not RecruitingNCT06253520
What this trial is testing
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Who this might be right for
Metastatic Solid CancersColorectal CancerBreast Cancer+4 more
National Cancer Institute (NCI) 210